Featured Research Search Results
Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer with a BRCA Mutation or a Biomarker Called HRD
Clinicaltrials.gov identifier:
NCT06580314
Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD
Phase 3
A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations
Clinicaltrials.gov identifier:
NCT04890613
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
Phase 1
Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs
Clinicaltrials.gov identifier:
NCT06167317
Treatment
Treatment study for people with advanced or metastatic solid tumors
Phase 1
A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)
Clinicaltrials.gov identifier:
NCT04251052
Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries
Study of the Drug Olvi-Vec in Women with Ovarian Cancer
Clinicaltrials.gov identifier:
NCT05281471
Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy
Phase 3
Understanding the Emotional and Social Experiences of Individuals Diagnosed with Ovarian Cancer
Surveys, Registries, Interviews
Survey for people diagnosed with ovarian cancer
New Treatment in People with Triple Negative Breast Cancer or Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT06022029
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
Phase 1
Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families
Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy
Clinicaltrials.gov identifier:
NCT05287451
Prevention
Prevention study for women at high risk for ovarian cancer
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
Clinicaltrials.gov identifier:
NCT02693535
Treatment
Cancer treatment study for people with advanced solid tumors
Phase 2
Self -Perception and Intimacy After the Cancer Experience (SPICE)
Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health
Cancer Experience Registry
Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer
Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors
Clinicaltrials.gov identifier:
NCT04657068
Treatment
Phase 1/2 treatment study for advanced solid tumors
Phase 1/2